US · Healthcare · Drug Manufacturers - General
EPS came in at -0.13 against a street estimate of -0.26 — a beat of 50.0%.
Analysts rate Merck & Company Inc a buy (15 buy, 11 hold, 0 sell out of 26) with an average price target of $152.96.
CONFIDENT Q2 organic growth accelerated to 4.1%. Life Science and Electronics strong; Healthcare pressured by Mavenclad generic entry. FY26 guidance raised. Bio-Techne acquisition on track. Q2 2026 APAC showed exceptional bioprocessing demand and geopolitical-driven stocking. China softness in academia/Discovery offset by manufacturing build-out. U.S. Mavenclad generic erosion accelerating. Analysts pressed Process Solutions inventory/2027 destocking visibility; management confirmed no 2026 risk, minimal guidance. Semiconductor materials sustainability questioned; Ben cited capacity constraints extending into 2027 as structural support. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.15% |
| Vanguard Capital Management, LLC | 6.53% |
| State Street Corp | 4.84% |
| Wellington Management Company LLP | 3.50% |
| Vanguard Portfolio Management, LLC | 2.73% |
| Geode Capital Management, LLC | 2.41% |
| JPMorgan Chase & Co | 2.15% |
| Charles Schwab Investment Management Inc | 2.02% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 MERCK & CO., INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Sales (Q2 2026): $16,607 million vs. $15,806 million (Q2 2025) — up 5.1% • Sales (6M 202 | 2026-08-07 |
| Results announced · Q3 2026 MERCK & CO., INC. - FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • 2Q 2026 Sales: $16,607 million (up 5% vs 2Q 2025: $15,806 million) • J | 2026-08-04 |
| Shareholder vote results · Q2 2026 MERCK & CO., INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Shareholder Meeting held May 26, 2026 • Total votes cast: approximately 1.857 billion | 2026-05-28 |
| Company announcement · Q2 2026 MERCK & CO., INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Merck closed an underwritten public offering of $6,000,000,000 in new debt securities on May | 2026-05-22 |
| Quarterly report · Q1 2026 MERCK & CO., INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Q1 2026 Sales: $16,286 million (vs. $15,529 million in Q1 2025) • Q1 2026 Net Loss: $(4, | 2026-05-04 |
| Results announced · Q2 2026 MERCK Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total Worldwide Sales: $16.3 billion (5% growth; 3% excluding foreign exchange) • GAAP Lo | 2026-04-30 |
| Proxy statement · Q2 2026 MERCK & CO., INC. — PROXY SUMMARY FOR RETAIL INVESTORS CEO TOTAL COMPENSATION Robert M. Davis (Chairman, CEO, President): • 2025 Base Salary: $1,650 | 2026-04-08 |
| Annual report FY2025 MERCK & CO., INC. - 2025 ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Total Company sales: $65,011 million (2025) vs. $64,168 million (2024) — growth of | 2026-02-24 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.85 / share ex-date Sep 15, 2026 · pay Oct 7, 2026 | 2026-09-15 |
| Dividend | $0.85 / share ex-date Jun 15, 2026 · pay Jul 8, 2026 | 2026-06-15 |
| Dividend | $0.85 / share ex-date Mar 16, 2026 · pay Apr 7, 2026 | 2026-03-16 |
| Dividend | $0.85 / share ex-date Dec 15, 2025 · pay Jan 8, 2026 | 2025-12-15 |
| Dividend | $0.81 / share ex-date Sep 15, 2025 · pay Oct 7, 2025 | 2025-09-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Merck & Company Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.